NeuroStar TMS Therapy was evaluated for efficacy and safety in the acute treatment of major depression in patients who had failed to receive satisfactory improvement from prior antidepressant medication.^* A six-week, randomized, placebo-controlled triple-blind study conducted at 23 premier research institutions around the world established the efficacy and safety of NeuroStar TMS Therapy in the treatment of depression.

In clinical trials involving 10,000 active treatments, Neurostar TMS Therapy proved to be a safe option for patients suffering from major depression with less than 5% of patients studied discontinuing treatment due to adverse events. The most common side effects associated with TMS treatment were scalp pain and discomfort at the site of administration.

* NeuroStar TMS Therapy^® is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode. Click here for full prescribing and safety information